Published on September 28, 2022

NEW YORK, N.Y. – September 27, 2022Castor, a leading provider of clinical trial technology to democratize clinical research, today announced the appointment of Andrew Sadler as Chief Product & Technology Officer (CPTO).

“Castor’s modular SaaS platform improves the clinical trial experience for patients, sites and sponsors, using technology to accelerate every step of the clinical trial journey,” said Derk Arts, CEO and founder of Castor. “Andrew’s appointment ensures we have the leadership in place to build the best eClinical SaaS platform while successfully serving our customers in a globally compliant way.”

As CPTO for Castor, Andrew Sadler, brings more than 25 years of experience building, growing and leading engineering teams from startups to enterprise tech companies such as Google and Oracle. In this new role, Sadler is responsible for helping Castor deliver on its vision of modernizing clinical research by continuing to expand the company’s product offering and capabilities.

“Achieving the future of clinical research will require a new generation of technology that is more open, connected, and intelligent,” said Sadler. “I am grateful to join the Castor team and lead the development of innovative solutions to make this future a reality.”

As a leading provider of clinical trial technology, Castor is well-positioned for continued growth. The company’s recent leadership appointment ensures innovations to a solid product and engineering foundation and will allow Castor to enter new markets and support all aspects of a clinical trial – from recruitment through delivery.

About Castor

Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture.

Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide.

For more information, visit Follow us on LinkedIn at


Dana Perotti, [email protected]

KKH Advisors
Kimberly Ha, [email protected]

Contact our team to learn about our eCconsent platform.

Schedule Demo